The Moores Cancer Center (MCC) at the University of California, San Diego (UCSD) is a matrix cancer center with 225 members from 18 university departments. Peer-reviewed funding for UCSD investigators is $102 million (direct cost), of which $32 million originates from the NCI. An additional $13.8 million from non-peer reviewed sources results in total direct cost funding of $115.8 Million. A new 270,000 sq ft multipurpose Cancer Center building opened in April, 2005. It is located on the UCSD campus, surrounded by several other major life science research institutes and 470 biotechnology companies in La Jolla, which is commonly referred to as the """"""""Golden Triangle"""""""" of biotechnology. The MCC is the only NCI designated comprehensive cancer center in this prolific cancer research region. Given this advantage, the long-term vision for the Moores Cancer Center is to become the major hub in Southern California for the discovery and testing of new agents for the prevention, diagnosis and treatment of cancer. The new MCC building was specifically designed to: (1) stimulate interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Cancer Prevention and Control, Basic Science, and Clinical and Translational Research;(2) assemble in a common and accessible site the extensive NCI supported Shared Resources, and (3) act as a central gathering site for cancer translational researchers within the public and private sectors of Southern California. Since the building's opening only one year ago, patient accrual to therapeutic clinical trials has more than doubled. This application reports on 11 Shared Resources and seven Research Programs which reflect the scientific strengths and goals of the MCC. Four programs are existing - Cancer Biology, Cancer Genetics, Cancer Prevention and Control, Cancer Symptom Control, and three are new- Hematologic Malignancies, Reducing Cancer Disparities, and Tumor Growth, Invasion and Metastasis. This application also summarizes our plans for the deployment of new therapeutics originating from research occurring in MCC laboratories and collaborating institutes. The leadership of the MCC, supported by the UCSD administration, places the highest priority on research discovery and its translation into meaningful advances to prevent, ameliorate and eliminate the burden of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023100-27S8
Application #
8533331
Study Section
Subcommittee G - Education (NCI)
Program Officer
Das, Rina
Project Start
1996-07-01
Project End
2014-04-30
Budget Start
2011-05-01
Budget End
2014-04-30
Support Year
27
Fiscal Year
2012
Total Cost
$725,058
Indirect Cost
$256,535
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Connor, Michael; Karunamuni, Roshan; McDonald, Carrie et al. (2017) Regional susceptibility to dose-dependent white matter damage after brain radiotherapy. Radiother Oncol 123:209-217
Ly, Peter; Teitz, Levi S; Kim, Dong H et al. (2017) Selective Y centromere inactivation triggers chromosome shattering in micronuclei and repair by non-homologous end joining. Nat Cell Biol 19:68-75
Sundaramoorthy, Sriramkumar; Garcia Badaracco, Adrian; Hirsch, Sophia M et al. (2017) Low Efficiency Upconversion Nanoparticles for High-Resolution Coalignment of Near-Infrared and Visible Light Paths on a Light Microscope. ACS Appl Mater Interfaces 9:7929-7940
D'Antonio, Matteo; Woodruff, Grace; Nathanson, Jason L et al. (2017) High-Throughput and Cost-Effective Characterization of Induced Pluripotent Stem Cells. Stem Cell Reports 8:1101-1111
Guo, Shicheng; Diep, Dinh; Plongthongkum, Nongluk et al. (2017) Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 49:635-642
Jiang, Qingfei; Crews, Leslie A; Holm, Frida et al. (2017) RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer 17:381-392
Krishnan, A P; Karunamuni, R; Leyden, K M et al. (2017) Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. AJNR Am J Neuroradiol 38:882-889
Martínez, María Elena; Gomez, Scarlett L; Tao, Li et al. (2017) Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat 166:185-193
Connor, Michael J; Marshall, Deborah C; Moiseenko, Vitali et al. (2017) Adverse Events Involving Radiation Oncology Medical Devices: Comprehensive Analysis of US Food and Drug Administration Data, 1991 to 2015. Int J Radiat Oncol Biol Phys 97:18-26
Panopoulos, Athanasia D; D'Antonio, Matteo; Benaglio, Paola et al. (2017) iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. Stem Cell Reports 8:1086-1100

Showing the most recent 10 out of 805 publications